Sonnet Biotherapeutics Holdings Inc

As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.